Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/13095
|
| Title: | Phase I dose-escalation study of SCB01A, a microtubule inhibitor with vascular disrupting activity, in patients with advanced solid tumors |
| Authors: | Shiah, HS;Chiang, NJ;Lin, CC;Yen, CJ;Tsai, HJ;Wu, SY;Su, WC;Chang, KY;Wang, CC;Chang, JY;Chen, LT |
| Contributors: | National Institute of Cancer Research |
| Abstract: | LESSONS LEARNED: SCB01A is a novel microtubule inhibitor with vascular disrupting activity. This first-in-human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity. SCB01A is safe and well-tolerated in patients with advanced solid malignancies with manageable neurotoxicity. BACKGROUND: SCB01A, a novel microtubule inhibitor, has vascular disrupting activity (VDA). METHODS: In this phase I dose-escalation and extension study, patients with advanced solid tumors were administered intravenous SCB01A infusions for 3 hours once every 21 days. Rapid titration and a 3+3 design escalated the dose from 2 mg/m(2) to the maximum tolerated dose (MTD) based on dose-limiting toxicity (DLT). SCB01A-induced cellular neurotoxicity was evaluated in dorsal root ganglion cells. The primary endpoint was MTD. Safety, pharmacokinetics (PK), and tumor response were secondary endpoints. RESULTS: Treatment-related adverse events included anemia, nausea, vomiting, fatigue, fever, and peripheral sensorimotor neuropathy. DLTs included grade (G)4 elevated creatine phosphokinase (CPK) in the 4 mg/m(2) cohort; G3 gastric hemorrhage in the 6.5 mg/m(2) cohort; G2 thromboembolic event in the 24 mg/m(2) cohort; G3 peripheral sensorimotor neuropathy, G3 elevated aspartate aminotransferase, and G3 hypertension in the 32 mg/m(2) cohort. The MTD was 24 mg/m(2) , and average half-life was ~2.5 hours. The area under the curve-dose response relationship was linear. Nineteen subjects were stable after two cycles. The longest treatment lasted 24 cycles. SCB01A-induced neurotoxicity was reversible in vitro. CONCLUSION: The MTD of SCB01A was 24 mg/m(2) every 21 days; it is safe and tolerable in patients with solid tumors. |
| Date: | 2021-04 |
| Relation: | Oncologist. 2021 Apr;26(4):e567-e579. |
| Link to: | http://dx.doi.org/10.1002/onco.13612 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1083-7159&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000599729500001 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85097816159 |
| Appears in Collections: | [陳立宗] 期刊論文
[張俊彥] 期刊論文
[張光裕] 期刊論文
[蔡慧珍] 期刊論文
[姜乃榕] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB33245172.pdf | | 10872Kb | Adobe PDF | 241 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
